Latvian LongeVC invested in US biotech Interface Biosciences

Latvian LongeVC invested in the US biotech Interface Biosciences, which develops inflammatory disease treatment. New investors from the US, San-Diego-based VC SeedFolio and Berlington-based Gaingels, as well as previous backers US-based Pacific 8 Ventures, Pear VC, Boom Capital, and Ulu Ventures also participated in the $3M seed round.

Founded in Palo Alto in 2020 by Stanford alumni with Ph. D.s Dr. Hannah C. Wastyk and Dr. Will Van Treuren, Interface Biosciences is an AI-enabled, metabolomics-based drug discovery platform. The startup's platform helps identify microbial metabolites, which are a source of natural product drug scaffolds. The scaffolds modulate the immune system and reduce inflammation, enabling novel treatments for various inflammatory diseases, such as eczema, inflammatory bowel disease, and rheumatoid arthritis. The startup prepares for IND-enabling studies. Interface Biosciences will use the investment to expand its research and develop the platform. 

LongeVC is a venture company with offices in Riga and Lugano (Switzerland). It was established in 2016 by Garri Zmudze, Sergey Jakimov, and Ilya Suharenko. A €35M fund backs biotech and longevity startups at the early and seed stages across the US and Europe. This year, LongeVC invested in San Francisco-based psychedelics startup Freedom Biosciences, US home kits for blood testing SiPhox Health, US startup Melio, which offers rapid diagnostic solutions for bloodstream infections, and US health tech startup AOA Dx.